PT  - JOURNAL ARTICLE
AU  - Ragupathi, Premalatha
AU  - Khamisani, Vaneezeh
AU  - Sadiq, Aisha Fadila
AU  - Mobiddo, Mariam Aylu
AU  - Rahamathullah, Nazeerullah
AU  - Bagchi, Sovan
AU  - Kamian, Ala
AU  - Parwaiz, Nasir
AU  - Akhtar, Mohammad Shahid
TI  - Prevalence of class A ESBL, class B and D carbapenemase encoding genes (CTX-M, TEM, SHV, NDM, IMP, OXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of United Arab Emirates
AID  - 10.1101/2024.01.26.24301841
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.26.24301841
4099  - http://medrxiv.org/content/early/2024/01/29/2024.01.26.24301841.short
4100  - http://medrxiv.org/content/early/2024/01/29/2024.01.26.24301841.full
AB  - Objective The aim of this study was to assess the prevalence of class A ESBL, class B and D carbapenemase encoding genes (blaCTX-M, blaTEM, blaSHV, blaNDM, blaIMP and blaOXA-48) in gram-negative bacterial pathogens isolated from various clinical samples collected from northern region of UAE.Methods A laboratory based experimental study was conducted from October 14, 2021, to June 30, 2022. A total of 3670 various clinical samples (urine, blood, pus, and sputum) were obtained from patients attending the in and out-patient departments of Thumbay University Hospital and various other hospitals of Northern Emirates of UAE, processed for routine bacterial culture examination and determined their antibiotic sensitivity pattern especially ESBL and carbapenem resistance using MicroScan Neg Breakpoint Combo 50 panel. Molecular detection of class A ESBL, class B and D carbapenemase encoding genes (blacTX-M, blaTEM, blaSHV blaNDM, blaIMP & blaOXA-48) were performed on the ESBL and carbapenemase producing gram negative bacteria. Partial genomic sequencing and phylogenetic tree analysis was performed on the most predominant ESBL gene blaCTX-M.Results In total, 1098 bacterial cultures were obtained, of which 833 were gram negative bacteria and among them, 209 (25.1%) were ESBL producers and 40 (4.8%) were both ESBL and carbapenemase producers. In all the 249 bacterial isolates, the ESBL and carbapenemase encoding genes (blaCTX-M, blaTEM, blaSHV, blaNDM & blaIMP) were detected except blaOXA-48. The blaCTX-M (n=72) was the predominantly harbored gene followed by blaTEM (n=56) and blaSHV (n=29), mostly detected in E. coli (n=157), then K. pneumoniae (n=41), P. aeruginosa (n=18) & A. baumannii (n=7). The blaNDM & blaIMP were detected in K. pneumoniae (n=4), A. baumannii (n=3) and P. aeruginosa (n=2) for blaIMP. The gene combinations such as blaCTX-M+TEM (n=15), blaCTX- M+SHV (n=15), blaCTX-M+TEM+blaSHV (n=6) were co-harbored in 36 E. coli and in the K. pneumoniae, the blaCTX-M+TEM (n=15), blaCTX-M+SHV (n=15), blaTEM+SHV (n=3), blaTEM+NDM (n=1) were detected. The blaCTX-M+TEM, blaCTX-M+SHV & blaCTX-M+TEM+SHV+IMP were detected in one P. aeruginosa and in one A. baumannii, the blaTEM+NDM, blaTEM+IMP & blaCTX-M+TEM+SHV+IMP were detected.Conclusion The highest bacterial culture positivity was detected in the urine samples. 25.1% of the Gram-ve bacteria were only ESBL producers and 4.8% were both the ESBL & carbapenemase producers. 44.5% of ESBL & carbapenemase producing bacteria harbored the blaCTX-M and mostly detected in the E. coli, then K. pneumoniae and P. mirabilis. Multiple gene combinations were detected in 5% P. aeruginosa, 10% A. baumannii and 3.82% E. coli. This finding highlights the importance of molecular detection of ESBL & carbapenemase producing genes to emphasize the monitor and control the development of multi drug resistant Gram-ve bacterial pathogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ref. no. IRB/COM/STD/101/Oct-2021 To, Maryam Aliyu Modibbo 2018BM01 Premalatha Ragupathi 2018BM14 Vaneezeh Khamisani 2018BM15 Aisha Fadila Sadiq 2018BM33 College of Medicine Gulf Medical University Ajman, UAE Subject: Institutional Review Board Approval Dear Student/s, Greetings from Gulf Medical University, Ajman. This is to inform you that the Institutional Review Board has reviewed your research project titled “Prevalence of class A ESBL genes blaCTX-M, blaTEM, blaSHV and carbapenemase producing genes blaNDM, blaIMP, blaOXA-48 in gram-negative bacterial pathogens isolated from various clinical samples (Urine, Blood, Sputum & Pus) in Ajman and Northern parts of UAE”. The study has been approved. You are required to report to your supervisors/cosupervisors Dr. Nazeerullah Rahamathullah, Assistant Professor, College of Medicine, GMU and Dr. Nasir Parwaz, Clinical Lecturer, College of Medicine, GMU. Thus, the IRB allows you to collect the data in relation to the above-mentioned research project retrospectively from Thumbay Laboratory, Thumbay University Hospital, Ajman since 1st September 2021. The data collected by you shall be used only for the purpose of conducting the research study. Any information obtained in connection with the study should be treated as confidential. Any violation of these terms and conditions will be treated as personal/ academic misconduct that may warrant further action in this regard. The requirement of Informed consent from the patient is waived and the patient's information/details will be kept anonymous.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNot applicable